AG Szymanski de Toledo

Philadelphia-negative myeloproliferative neoplasms (Ph-MPNs) comprises a group of complex and heterogeneous hematological malignancies characterized by the abnormal expansion of clonal stem cell populations. Despite the available therapeutic options and the growing body of knowledge on disease development and targetable vulnerabilities, the only therapeutic option with curative potential is allogeneic stem cell transplantation.

The research group of Dr. Marcelo A. Szymanski de Toledo is focused on unveiling novel molecular and cellular targets in Ph-MPNs. We employ different cell lines, murine models, patient primary samples and patient-specific induced pluripotent stem cells (iPSC) to identify targetable cellular crosstalk and deregulated pathways in MPN. Understanding how the malignant clone interacts and remodels the bone marrow environment may reveal novel therapeutic avenues in MPN.

Our ongoing projects are:

  • Dissecting the role of mast cells in MPN-associated inflammation and BM fibrosis.
  • Investigate the role of neoplastic angiogenesis and dysregulated VEGFR signaling in MPN.
  • Recapitulating in vitro the human BM niche with CRISPR/Cas-engineered patient-specific induced pluripotent stem cells (iPSCs) and biomaterials.

Our projects are funded by:


José Carreras Leukämie-Stiftung



Group Leader

Dr. rer. nat. Marcelo A. Szymanski de Toledo
Tel.: 0241 80 80986

Team Member

Cristina Baquero Lopez, M.Sc. (PhD-Doktorandin)



For a complete reference list please see PubMed* Link